As reported by Chu et al. [25], their DNA vaccine, which comprised a modified core peptide of mucin1 (PDTRP) and a GM-CSF coding sequence at the C-terminus, induced better protection against tumor challenge, and that protection was correlated with type 2 immune responses manifested by an increased IgG1 to IgG2a antibody ratio and greater induction of GATA-3 and IL-4 mRNA than of T-bet and IFN-γ mRNA in spleen cells of vaccinated mice. Here, IL4 is linked to neoplasm.